NCT01900496 (Clinical Trial/ Brentuximab vedotin)

Study Title
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma (NCT01900496)

Trial Description
This research is being done to study a combination of brentuximab vedotin (also known as SGN-035) and rituximab for the treatment of relapsed Hodgkin lymphoma (HL).

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center. [1]

Study Data

• Condition: Lymphoma
• Interventions:
  • Drugs used in this trial:
    • Brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
    • Rituximab (Rituxam®; Biogen, Inc,/ Genentech, Inc.)
• Phase: 0
• Estimated Enrollment: 25
• Start: April 2014
• Estimated Completion: June 2019
• Last verified: June 2014

Study Schematic

Last Editorial review: July 7, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.